Monovalent Properdin Antibodies for Alternative Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Uncontrolled activation or insufficient regulation of the alternative complement pathway leads to systemic inflammation and tissue damage, necessitating a need for effective regulation of properdin activity to mitigate associated diseases.
Innovation Solution
Development of monovalent antibodies and antibody fragments that selectively bind to properdin, inhibiting the alternative complement pathway activation and reducing immune complex aggregation, thereby stabilizing the C3 and C5 convertase complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bivalent antibodies are used to bind properdin, then binding affinity is improved, but immune complex aggregation and toxicity occur
Solution Approach 1:
The patent applies segmentation by dividing the bivalent antibody into separate monovalent antibody entities. Each monovalent antibody binds to a single properdin molecule through its single antigen-binding site, preventing the formation of large aggregated immune complexes while maintaining effective properdin inhibition. This is achieved by engineering antibodies with only one functional binding site instead of two.
Solution Approach 2:
The patent employs partial action by using monovalent antibodies that provide just enough binding capacity to inhibit properdin function without the excessive binding that leads to aggregation. The single binding site per antibody molecule is sufficient to block alternative complement pathway activation without creating the multivalent cross-linking that causes harmful immune complex formation.
2Object-affected harmful factors
If properdin activity is inhibited to treat alternative complement pathway dysregulation, then disease symptoms are mitigated, but membrane attack complex assembly is blocked
Solution Approach 1:
The patent applies parameter changes by modifying the binding characteristics of the antibody to properdin. By creating monovalent antibodies with specific affinity ranges and binding kinetics, the therapy achieves sufficient inhibition of pathologic complement activation while allowing physiologic complement functions to proceed. The binding parameters are optimized to distinguish between pathologic and physiologic states.
Solution Approach 2:
The patent applies local quality by targeting specific epitopes on properdin that are critical for alternative pathway activation but not required for physiologic functions. The monovalent antibodies are designed to bind to particular regions of properdin (such as the C-terminal domain) to selectively inhibit pathologic activation while preserving normal complement-mediated immune defense.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monovalent antibodies effectively inhibit alternative complement pathway-induced membrane attack complex assembly, providing clinical benefits for patients with diseases mediated by alternative complement pathway dysregulation, such as autoimmune thrombotic thrombocytopenic purpura and other conditions.
Implementation Method 1
isolated monovalent antibodies and antibody fragments thereof that specifically or substantially specifically bind properdin
Implementation Method 2
By inhibiting the functional activity of properdin, the monovalent antibody described herein inhibits alternative complement pathway-induced assembly of the membrane attack complex
Data Source
AI summary
Described herein are isolated monovalent antibodies or antibody fragments thereof that bind human properdin. Such antibodies are useful in methods of treatment for diseases mediated by alternative complement pathway dysregulation.